STOK

TentativeAI MemoPost-earnings T+3

Stoke Therapeutics

As of 2026-08-13/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

medium

Horizon

—

Key catalyst

Post-earnings update: EMPEROR enrollment complete and regulatory path advances • 2026-11-11

Base target: $34 / p=50% prob

Biggest risk

The core value driver remains an unreported, blinded Phase 3 outcome. Open-label evidence may not replicate in a controlled trial, FDA statistical or package requirements could delay filing, and early STK-002 data are not yet available. No post-print analyst revisions, target changes, or estimate revisions are available in the packet.

Invalidation

Break below $20 or thesis failure.

What would change my mind?

Rapid EMPEROR enrollment, no reported treatment discontinuations, supportive longitudinal open-label data, a planned regulatory sequence, and approximately $420 million of pro forma cash support the possibility of a successful zorevunersen launch path. The STK-002 program adds longer-term platform optionality.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-13

Base target

$34

p=50%

Bull target

$48

p=25%

Bear target

$20

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Binary Phase 3 and regulatory execution risk
STK-002 ADOA development milestone
Rapid EMPEROR enrollment, no reported treatment discontinuations, supportive longitudinal open-label data, a planned regulatory sequence, and approximately $420 million of pro forma cash support the possibility of a successful zorevunersen launch path.

BearKey bullets

Cash runway depends on execution, development costs, and potential partner milestone assumptions.
FDA alignment on the statistical analysis plan and rolling NDA package could affect timing or approval prospects.
Phase 3 EMPEROR efficacy remains unreported and is the primary binary risk.

WatchKey bullets

Post-earnings update: EMPEROR enrollment complete and regulatory path advances

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $34 (p=50%)

Target spread vs base: +41% / -41%

Scenario probabilities

Bull Target: $48 (p=25%)Base Target: $34 (p=50%)Bear Target: $20 (p=25%)

Commentary

The confirmed company Q2 update is constructive on EMPEROR enrollment, cash runway, and regulatory preparation, but it does not establish a Phase 3 efficacy surprise and the pivotal readout remains distant. No trustworthy post-print price reaction, analyst target change, estimate revision, or social signal is available in the packet. The evidence supports cautious monitoring rather than a stronger post-earnings directional thesis.

As of 2026-08-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Binary Phase 3 and regulatory execution risk
STK-002 ADOA development milestone

Scenarios

Bull Target (Scenario probability)

$48 / p=25% prob

Base Target (Scenario probability)

$34 / p=50% prob

Bear Target (Scenario probability)

$20 / p=25% prob

Analysis 2026-08-13 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-11
Post-earnings update: EMPEROR enrollment complete and regulatory path advances
The company’s August 3 Q2 business update reported completion of enrollment for 162 patients in the Phase 3 EMPEROR study, with a data readout anticipated in Q3 2027. Stoke expects a pre-NDA meeting with the FDA in H2 2026 and plans to initiate a rolling U.S. NDA in Q1 2027. Pro forma cash of approximately $420 million is expected to fund operations toward potential early-2028 commercialization. [#SEC-8K-2026-08-03]
Prob 75.00% • Move 8.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Binary Phase 3 and regulatory execution risk
2026-11-11
EMPEROR remains blinded and pivotal efficacy data are not expected until Q3 2027. The investment case depends on controlled Phase 3 results validating earlier open-label data, successful FDA alignment, and timely NDA execution. [#SEC-8K-2026-08-03]
Prob 60% • Move -20% • Priced-in 40%

Long-term Catalysts

Months to a year

STK-002 ADOA development milestone
2027-08-13
Dose escalation is continuing in the Phase 1 OSPREY study of STK-002, with initial safety and efficacy data anticipated in H1 2027. The program provides platform and pipeline optionality but remains early stage. [#SEC-8K-2026-08-03]
Prob 45% • Move 12% • Priced-in 35%

Risks

Cash runway depends on execution, development costs, and potential partner milestone assumptions.
FDA alignment on the statistical analysis plan and rolling NDA package could affect timing or approval prospects.
Phase 3 EMPEROR efficacy remains unreported and is the primary binary risk.
Recent Form 4 records show open-market sales by the chief medical officer; these support insider-activity monitoring only. [#SEC-FORM4-2026-08-05]
STK-002 remains an early-stage program with limited patient exposure and no efficacy data yet.
The packet does not provide a reliable post-earnings price-reaction, analyst-revision, or estimate-revision signal.

Peers

Symbol	Summary
BHVN	Same-sector, similar-market-cap screening peer; the packet provides no direct Dravet or zorevunersen comparability, so valuation inference is weak.
GHRS	Same-sector, similar-market-cap screening peer; useful only as a broad biotech reference because no direct program or indication comparison is supplied.
REGN	Large-cap biotechnology benchmark with materially different scale and business mix; weak operating comparability to STOK.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-13

Loading AI feed…

Symbol

Summary

BHVN

Same-sector, similar-market-cap screening peer; the packet provides no direct Dravet or zorevunersen comparability, so valuation inference is weak.

GHRS

Same-sector, similar-market-cap screening peer; useful only as a broad biotech reference because no direct program or indication comparison is supplied.

REGN

Large-cap biotechnology benchmark with materially different scale and business mix; weak operating comparability to STOK.